BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21106223)

  • 1. The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo.
    Massi D; Fondi C; Nozzoli C; Benemei S; Lapi F; Albarello L; Avellini C; Bonoldi E; Casini M; Cesinaro AM; Ciceri F; Colombetti V; Comin CE; Donelli A; Fortunato M; Fratoni S; Guidi S; Messerini L; Milone G; Rapezzi D; Negri G; Patriarca F; Peccatori FA; Ponzoni M; Rafaniello P; Raimondi R; Salomone E; Tendas A; Villari L; Santucci M; Bosi A
    Hum Pathol; 2011 Feb; 42(2):254-68. PubMed ID: 21106223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW; Gorgun G; Miller KB; Foss FM
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.
    Schetelig J; Kröger N; Held TK; Thiede C; Krusch A; Zabelina T; Dubiel M; Rick O; Bornhäuser M; Ehninger G; Zander AR; Siegert W
    Haematologica; 2002 Mar; 87(3):299-305. PubMed ID: 11869943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors.
    Shaw BE; Russell NH; Devereux S; Das-Gupta E; Mackinnon S; Madrigal JA; Pagliuca A; Mufti GJ; Byrne JL
    Haematologica; 2005 Nov; 90(11):1562-9. PubMed ID: 16266905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
    Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
    Couriel DR; Saliba RM; Giralt S; Khouri I; Andersson B; de Lima M; Hosing C; Anderlini P; Donato M; Cleary K; Gajewski J; Neumann J; Ippoliti C; Rondon G; Cohen A; Champlin R
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):178-85. PubMed ID: 14993883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
    Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
    Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.